36
Participants
Start Date
October 30, 2024
Primary Completion Date
October 31, 2025
Study Completion Date
December 31, 2025
BT-114143 Injection at low dose
A total of 10 subjects were enrolled. All of them received BT-114143 Injection at low dose. BT-114143 will be administered twice daily for three consecutive days.
BT-114143 Injection at Medium-dose
A total of 10 subjects were enrolled. All of them received BT-114143 Injection at Medium-dose. BT-114143 will be administered twice daily for three consecutive days.
BT-114143 Injection at High-dose
A total of 10 subjects were enrolled. All of them received BT-114143 Injection at High-dose. BT-114143 will be administered twice daily for three consecutive days.
control group
The ratio of subjects in the experimental group to those in the control group is 10:3, with 3 placebo - treated control subjects corresponding to each dose group. The subjects will receive placebo treatment twice a day for 3 consecutive days.
RECRUITING
Peking Union Medical College Hospital, Beijing
ScinnoHub Pharmaceutical Co., Ltd.
INDUSTRY